| Autor: |
Jean-Baptiste Latouche, Jérôme Galon, Thierry Frébourg, Pierre Michel, Jean-Christophe Sabourin, Jean-Jacques Tuech, Richard Sesboüé, Florence Le Pessot, Jacques Mauillon, Jacques Benichou, Jérôme Leprince, Aurélie Drouet, Emilie Fauquembergue, Nicolas Elie, Tessa Fredriksen, Helen K. Angell, Gabriela Bindea, Hafid Kora, Bernhard Mlecnik, Mohamad Hamieh, David Tougeron, Pauline Maby |
| Rok vydání: |
2023 |
| Popis: |
Colorectal cancers with microsatellite instability (MSI) represent 15% of all colorectal cancers, including Lynch syndrome as the most frequent hereditary form of this disease. Notably, MSI colorectal cancers have a higher density of tumor-infiltrating lymphocytes (TIL) than other colorectal cancers. This feature is thought to reflect the accumulation of frameshift mutations in sequences that are repeated within gene coding regions, thereby leading to the synthesis of neoantigens recognized by CD8+ T cells. However, there has yet to be a clear link established between CD8+ TIL density and frameshift mutations in colorectal cancer. In this study, we examined this link in 103 MSI colorectal cancers from two independent cohorts where frameshift mutations in 19 genes were analyzed and CD3+, CD8+, and FOXP3+ TIL densities were quantitated. We found that CD8+ TIL density correlated positively with the total number of frameshift mutations. TIL densities increased when frameshift mutations were present within the ASTE1, HNF1A, or TCF7L2 genes, increasing even further when at least one of these frameshift mutations was present in all tumor cells. Through in vitro assays using engineered antigen-presenting cells, we were able to stimulate peripheral cytotoxic T cells obtained from colorectal cancer patients with peptides derived from frameshift mutations found in their tumors. Taken together, our results highlight the importance of a CD8+ T cell immune response against MSI colorectal cancer–specific neoantigens, establishing a preclinical rationale to target them as a personalized cellular immunotherapy strategy, an especially appealing goal for patients with Lynch syndrome. Cancer Res; 75(17); 3446–55. ©2015 AACR. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
